Plus Therapeutics (PSTV) Stock Overview
A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PSTV Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Plus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$2.31 |
| 52 Week Low | US$0.16 |
| Beta | 0.67 |
| 1 Month Change | 40.81% |
| 3 Month Change | 54.22% |
| 1 Year Change | -66.25% |
| 3 Year Change | -95.41% |
| 5 Year Change | -98.58% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully
Aug 15
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.Shareholder Returns
| PSTV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.4% | 3.8% | 1.3% |
| 1Y | -66.3% | -8.1% | 15.8% |
Return vs Industry: PSTV underperformed the US Biotechs industry which returned -8.1% over the past year.
Return vs Market: PSTV underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| PSTV volatility | |
|---|---|
| PSTV Average Weekly Movement | 31.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PSTV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PSTV's weekly volatility has decreased from 56% to 32% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 21 | Marc Hedrick | plustherapeutics.com |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.
Plus Therapeutics, Inc. Fundamentals Summary
| PSTV fundamental statistics | |
|---|---|
| Market cap | US$53.22m |
| Earnings (TTM) | -US$19.03m |
| Revenue (TTM) | US$5.32m |
Is PSTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSTV income statement (TTM) | |
|---|---|
| Revenue | US$5.32m |
| Cost of Revenue | US$8.05m |
| Gross Profit | -US$2.73m |
| Other Expenses | US$16.30m |
| Earnings | -US$19.03m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | -51.33% |
| Net Profit Margin | -357.85% |
| Debt/Equity Ratio | 0% |
How did PSTV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/19 21:40 |
| End of Day Share Price | 2025/08/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Plus Therapeutics, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |